Apollo Endosurgery, Inc. (NASDAQ:APEN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Apollo Endosurgery, Inc. (NASDAQ:APEN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Director Resignation
On April 6, 2017, Jack Nielsen, member of the Board of Directors (the “Board”) of Apollo Endosurgery, Inc. (the “Company”) and Chairman of the Compensation Committee, informed the Board of his decision not to stand for reelection at the Company’s 2017 Annual Meeting of Stockholders to be held on June 9, 2017 (the “Annual Meeting”). Mr. Nielsen will continue to serve on the Board and as Chairman of the Compensation Committee until the Annual Meeting. Mr. Nielsen’s decision not to stand for re-election is not due to any disagreement with the Company.
Following the Annual Meeting, the Board will decrease the size of the Board from nine to eight directors to Article II, Section 2(b) of the Company’s bylaws.
About Apollo Endosurgery, Inc. (NASDAQ:APEN)
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract. Apollo Endosurgery, Inc. (NASDAQ:APEN) Recent Trading Information
Apollo Endosurgery, Inc. (NASDAQ:APEN) closed its last trading session down -0.26 at 13.00 with 6,277 shares trading hands.
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract. Apollo Endosurgery, Inc. (NASDAQ:APEN) Recent Trading Information
Apollo Endosurgery, Inc. (NASDAQ:APEN) closed its last trading session down -0.26 at 13.00 with 6,277 shares trading hands.
